Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Adeno-associated viral vectors are highly safe and efficient gene delivery vehicles. However, numerous challenges in vector design remain, including neutralizing antibody responses, tissue transport and infection of resistant cell types. Changes must be made to the viral capsid to overcome these problems; however, very often insufficient information is available for rational design of improvements. We therefore applied a directed evolution approach involving the generation of large mutant capsid libraries and selection of adeno-associated virus (AAV) 2 variants with enhanced properties. High-throughput selection processes were designed to isolate mutants within the library with altered affinities for heparin or the ability to evade antibody neutralization and deliver genes more efficiently than wild-type capsid in the presence of anti-AAV serum. This approach, which can be extended to additional gene delivery challenges and serotypes, directs viral evolution to generate 'designer' gene delivery vectors with specified, enhanced properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, directed evolution has been applied to generate AAV variants capable of evading neutralizing antibodies in vitro and in vivo.68–72”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“New AAV variants created through directed evolution withstood up to 35-fold higher in vitro concentrations of pooled human antibodies than AAV2.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“These antibody neutralization properties also led to enhanced transduction in vivo, where AAV variants were capable of significantly higher transduction in the liver, heart and muscle than AAV2 in mice passively immunized with human antibodies.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“Compared with natural variants, the engineered AAV-DJ variant, consisting of residues from AAV2, AAV8, and AAV9 variants, has been shown to transduce hepatocytes in the presence of human intravenous IgG [194, 195].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [194]
In the citing paper
“The best-performing variants selected from this screen were reported to evade antibodies and enhance the gene expression [88].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [88]
Citations
Cites
Rapid evolution of a protein in vitro by DNA shuffling
Stemmer, W. P. C. (1994) · Nature · doi:10.1038/370389a0 · Cited by 1,932
Yeast surface display for screening combinatorial polypeptide libraries
Boder, E. T., & Wittrup, K. D. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-553 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo
Lai, K., Kaspar, B. K., Gage, F. H., & Schaffer, D. V. (2003) · Nature Neuroscience · doi:10.1038/nn983 · Cited by 799
Self-citationRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Cited by
Items 101–200 of 535
Ojala, D. S., Sun, S., Santiago-Ortiz, J. L., Shapiro, M. G., Romero, P. A., & Schaffer, D. V. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.006 · Cited by 97
Self-citationGene therapy: The first two decades and the current state‐of‐the‐art
Flotte, T. R. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21173 · Cited by 118
“Finally, rAAV has been subjected to in vitro evolution, using DNA shuffling between available serotype sequences to create a library of novel genomic variants (Schaffer andMaheshri, 2004; Koerber et al., 2006; Maheshri et al., 2006; Perabo et al., 2006).”
MethodIn Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy
Choudhury, S. R., Fitzpatrick, Z., Harris, A. F., Maitland, S. A., Ferreira, J. S., Zhang, Y., Ma, S., Sharma, R. B., Gray-Edwards, H. L., Johnson, J. A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.84 · Cited by 113
Hareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
Engineering the AAV capsid to optimize vector–host-interactions
Büning, H., Huber, A., Zhang, L. N., Meumann, N., & Hacker, U. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.08.002 · Cited by 127
Choudhury, S. R., Harris, A. F., Cabral, D. J., Keeler, A. M., Sapp, E., Ferreira, J. S., Gray-Edwards, H. L., Johnson, J. A., Johnson, A. K., Su, Q., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.231 · Cited by 113
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108
“In their proof-of-principle study, Märsch and colleagues focused on five immunogenic sites: positions 449, 558, 459, 551, and 493 (Maheshri et al., 2006; Perabo et al., 2006; Maersch et al., 2009), which were subjected to saturation mutagenesis.”
BackgroundMethodInfluentialGene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
Grimm, D., & Zolotukhin, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.173 · Cited by 106
Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., & Wilson, J. M. (2015) · Molecular Therapy · doi:10.1038/mt.2015.179 · Cited by 107
Machine learning to navigate fitness landscapes for protein engineering
Freschlin, C. R., Fahlberg, S. A., & Romero, P. A. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102713 · Cited by 107
“Protein engineering aims to realize this potential by altering protein functions for applications in biotechnology, industry, and medicine [1–3].”
BackgroundNanobody-Enhanced Targeting of AAV Gene Therapy Vectors
Eichhoff, A. M., Börner, K., Albrecht, B., Schäfer, W., Baum, N., Haag, F., Körbelin, J., Trepel, M., Braren, I., Grimm, D., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.003 · Cited by 106
Stanimirovic, D. B., Sandhu, J. K., & Costain, W. J. (2018) · BioDrugs · doi:10.1007/s40259-018-0309-y · Cited by 105
In vivo–directed evolution of adeno-associated virus in the primate retina
Byrne, L. C., Day, T. P., Visel, M., Strazzeri, J. A., Fortuny, C., Dalkara, D., Merigan, W. H., Schaffer, D. V., & Flannery, J. G. (2020) · JCI Insight · doi:10.1172/jci.insight.135112 · Cited by 104
Self-citationShen, S., Horowitz, E. D., Troupes, A. N., Brown, S. M., Pulicherla, N., Samulski, R. J., Agbandje-McKenna, M., & Asokan, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.482380 · Cited by 104
“1A), viral particles were eluted from the heparin affinity column in peak fractions at a concentration of 450 mM saline, consistent with previous publications (6, 21).”
ResultEngineering the AAV capsid to evade immune responses
Barnes, C., Scheideler, O., & Schaffer, D. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.002 · Cited by 102
Self-citationSystemic delivery of adeno-associated viral vectors
Duan, D. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.07.006 · Cited by 103
Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site
Huang, L.-Y., Patel, A., Ng, R., Miller, E. B., Halder, S., McKenna, R., Asokan, A., & Agbandje-McKenna, M. (2016) · Journal of Virology · doi:10.1128/jvi.00161-16 · Cited by 101
“Capsid modifications such as mutations at critical antigenic sites (24) and rational capsid residue substitutions and insertion (25) have been used to generate antibody escape variants, as well as vectors with enhanced transduction.”
BackgroundJang, J.-H., Koerber, J. T., Kim, J.-S., Asuri, P., Vazin, T., Bartel, M., Keung, A., Kwon, I., Park, K. I., & Schaffer, D. V. (2011) · Molecular Therapy · doi:10.1038/mt.2010.287 · Cited by 101
Self-citationVEGAS as a Platform for Facile Directed Evolution in Mammalian Cells
English, J. G., Olsen, R. H. J., Lansu, K., Patel, M., White, K., Cockrell, A. S., Singh, D., Strachan, R. T., Wacker, D., & Roth, B. L. (2019) · Cell · doi:10.1016/j.cell.2019.05.051 · Cited by 107
“Sindbis Virus for Directed Evolution in Mammalian Cell Culture Mammalian cell-based directed evolution has had many successes (Armbruster et al., 2007; Berman et al., 2018; Buchholz et al., 1998; Chan et al., 2017; Hess et al., 2016; Maheshri et al., 2006), albeit using time consuming, costly, and specialized screenin…”
BackgroundMiRNA inhibition in tissue engineering and regenerative medicine
Beavers, K. R., Nelson, C. E., & Duvall, C. L. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.006 · Cited by 108
Li, C., Diprimio, N., Bowles, D. E., Hirsch, M. L., Monahan, P. E., Asokan, A., Rabinowitz, J., Agbandje-McKenna, M., & Samulski, R. J. (2012) · Journal of Virology · doi:10.1128/jvi.00675-12 · Cited by 96
“The second approach is to use error-prone PCR to generate a library of AAV variants and select for NAb escape mutants in the presence of NAb in vitro (31, 41, 56).”
BackgroundMethodGene Therapy for the Nervous System: Challenges and New Strategies
Maguire, C. A., Ramirez, S. H., Merkel, S. F., Sena‐Esteves, M., & Breakefield, X. O. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0299-5 · Cited by 107
“Vectors that can evade neutralizing antibodies have also been selected using DNA shuffling [57, 64].”
MethodAAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R. (2010) · Current Gene Therapy · doi:10.2174/156652310793180706 · Cited by 96
Viral-mediated gene therapy for the muscular dystrophies: Successes, limitations and recent advances
Odom, G. L., Gregorevic, P., & Chamberlain, J. S. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.09.007 · Cited by 114
Liu, Q., Huang, W., Zhang, H., Wang, Y., Zhao, J., Song, A., Xie, H., Zhao, C., Gao, D., & Wang, Y. (2014) · Gene Therapy · doi:10.1038/gt.2014.47 · Cited by 93
The Promise and Challenge of In Vivo Delivery for Genome Therapeutics
Wilson, R. C., & Gilbert, L. A. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00680 · Cited by 102
CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes
Steines, B., Dickey, D. D., Bergen, J., Excoffon, K. J. D. A., Weinstein, J. R., Li, X., Yan, Z., Alaiwa, M. H. A., Shah, V. S., Bouzek, D. C., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88728 · Cited by 92
Self-citationEvading the immune response upon in vivo gene therapy with viral vectors.
Sack, B. K., & Herzog, R. W. (2009) · PubMed · Cited by 106
Körbelin, J., Sieber, T., Michelfelder, S., Lunding, L., Spies, E., Hunger, A., Alawi, M., Rapti, K., Indenbirken, D., Müller, O. J., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.62 · Cited by 87
Müller cells as a target for retinal therapy
Devoldere, J., Peynshaert, K., Smedt, S. C. D., & Remaut, K. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.01.023 · Cited by 97
Li, Y., Zeng, H., Xu, R., Liu, B., & Li, Z. (2009) · Stem Cells · doi:10.1002/stem.234 · Cited by 88
Li, W., Zhang, L., Johnson, J. S., Zhijian, W., Grieger, J. C., Ping-Jie, X., Drouin, L. M., Agbandje-McKenna, M., Pickles, R. J., & Samulski, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.155 · Cited by 87
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 87
Koerber, J. T., Maheshri, N., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Protocols · doi:10.1038/nprot.2006.93 · Cited by 92
Self-citationReplacing Antibodies: Engineering New Binding Proteins
Banta, S., Dooley, K., & Shur, O. (2013) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071812-152412 · Cited by 86
Little Vector, Big Gene Transduction: Fragmented Genome Reassembly of Adeno-associated Virus
Hirsch, M. L., Agbandje-McKenna, M., & Jude Samulski, R. (2010) · Molecular Therapy · doi:10.1038/mt.2009.280 · Cited by 85
AAV Ancestral Reconstruction Library Enables Selection of Broadly Infectious Viral Variants
Santiago-Ortiz, J., Ojala, D. S., Westesson, O., Weinstein, J. R., Wong, S. Y., Steinsapir, A., Kumar, S., Holmes, I., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2015.74 · Cited by 83
Self-citationEvading and overcoming AAV neutralization in gene therapy
Earley, J., Piletska, E. V., Ronzitti, G., & Piletsky, S. A. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.11.006 · Cited by 93
Potential Use of Gene Transfer in Athletic Performance Enhancement
Baoutina, A., Alexander, I. E., Rasko, J. E. J., & Emslie, K. R. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300278 · Cited by 89
Liver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
“The success of this technique is highlighted by the development of AAV2 variants that can withstand significantly higher neutralizing antibody concentrations [108], as well as the development of variants that have enhanced antibody evasion, requiring ~20-fold higher antibody concentrations for neutralization [120].”
MethodIn vitro 'sexual' evolution through the PCR-based staggered extension process (StEP)
Zhao, H., & Zha, W. (2006) · Nature Protocols · doi:10.1038/nprot.2006.309 · Cited by 95
“Most recently, the StEP method was used to evolve adeno-associated virus with enhanced properties such as a better ability to evade antibody neutralization for gene deliver”
MethodSystemic gene delivery to the central nervous system using Adeno-associated virus
Bourdenx, M., Dutheil, N., Bezard, E., & Dehay, B. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00050 · Cited by 79
“…from the European Commission (to Benjamin Dehay); by a grant from the Fondation pour la Recherche Médicale (to Benjamin Dehay); by Agence Nationale de la Recherche Grants ANR-08-MNP-018 and ANR-07-MNPTrafinlid (to Erwan Bezard) and Mathieu Bourdenx is a recipient of an MESR fellowship.”
BackgroundMethodChowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Common Gene Therapy Viral Vectors Do Not Efficiently Penetrate Sputum from Cystic Fibrosis Patients
Hida, K., Lai, S. K., Suk, J. S., Won, S. Y., Boyle, M., & Hanes, J. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019919 · Cited by 80
“This approach is exemplified by previous work that evolved AAV vectors more efficient at CFTR delivery to human ciliated airway epithelium, or AAV vectors that evade neutralizing antibodies [50,51].”
BackgroundNisanov, A. M., de Jesús, J. A. R., & Schaffer, D. V. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.056 · Cited by 92
“In 2006 Maheshri et al. 29 generated a diverse AAV2 capsid library us-ing random point mutagenesis and recombination, followed by selective pressure to isolate variants with improved properties.”
Self-citationMichelfelder, S., Kohlschütter, J., Skorupa, A., Pfennings, S., Müller, O., Kleinschmidt, J. A., & Trepel, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005122 · Cited by 75
“Furthermore, novel AAV library principles like sequence evolution by errorprone PCR [62] and DNA shuffling [63] might enhance specificity and efficiency if used for in vivo selection.”
BackgroundHu, F., Kamigaki, T., Zhang, Z., Zhang, S., Dan, U., & Dan, Y. (2019) · Neuron · doi:10.1016/j.neuron.2019.09.019 · Cited by 74
Han, X., Alameh, M., Xu, Y., Palanki, R., El-Mayta, R. D., Dwivedi, G., Swingle, K. L., Xu, J., Gong, N., Xue, L., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01267-7 · Cited by 90
“Directed evolution is a powerful, high-throughput engineering approach that has been successfully utilized to generate adeno-associated viruses with enhanced transduction efficiency and tissue tropism 39,40 .”
Gene therapy progress and prospects: Duchenne muscular dystrophy
Foster, K., Foster, H., & Dickson, J. G. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302877 · Cited by 85
Marsic, D., Govindasamy, L., Currlin, S., Markusic, D. M., Tseng, Y.-S., Herzog, R. W., Agbandje-McKenna, M., & Zolotukhin, S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.139 · Cited by 72
Raguram, A., An, M., Chen, P., & Liu, D. R. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02467-x · Cited by 90
Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS
Kanaan, N. M., Sellnow, R. C., Boye, S. L., Coberly, B., Bennett, A., Agbandje-McKenna, M., Sortwell, C. E., Hauswirth, W. W., Boye, S. E., & Manfredsson, F. P. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.011 · Cited by 72
Genome engineering: a new approach to gene therapy for neuromuscular disorders
Nelson, C. E., Robinson-Hamm, J. N., & Gersbach, C. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.126 · Cited by 76
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
Advances in AAV Vector Development for Gene Therapy in the Retina
Day, T. P., Byrne, L. C., Schaffer, D. V., & Flannery, J. G. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_86 · Cited by 71
Self-citationGenetic therapy for the nervous system
Bowers, W. J., Breakefield, X. O., & Sena‐Esteves, M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr110 · Cited by 74
The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes
Wang, J., Faust, S. M., & Rabinowitz, J. E. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.017 · Cited by 75
Srivastava, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.014 · Cited by 71
Tseng, Y.-S., Gurda, B. L., Chipman, P., McKenna, R., Afione, S., Chiorini, J. A., Muzyczka, N., Olson, N. H., Baker, T. S., Kleinschmidt, J., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02710-14 · Cited by 70
Ying, Y., Müller, O. J., Goehringer, C., Leuchs, B., Trepel, M., Katus, H. A., & Kleinschmidt, J. A. (2010) · Gene Therapy · doi:10.1038/gt.2010.44 · Cited by 74
Bone tissue engineering and repair by gene therapy
Betz, V. (2008) · Frontiers in Bioscience · doi:10.2741/2724 · Cited by 69
“These challenges are currently addressed by developing vectors with enhanced tropism and less immunogenity (64, 65).”
Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications
Tsoras, A. N., & Champion, J. A. (2019) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-060718-030347 · Cited by 75
Critical assessment of current adeno-associated viral vector production and quantification methods
Aucoin, M. G., Perrier, M., & Kamen, A. (2007) · Biotechnology Advances · doi:10.1016/j.biotechadv.2007.09.001 · Cited by 71
Hsu, H.-L., Brown, A., Loveland, A. B., Lotun, A., Xu, M., Luo, L., Xu, G., Li, J., Ren, L., Su, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17047-1 · Cited by 63
Structure of neurotropic adeno-associated virus AAVrh.8
Halder, S., Van Vliet, K., Smith, J. K., Duong, T. T. P., McKenna, R., Wilson, J. M., & Agbandje-McKenna, M. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.08.017 · Cited by 64
“…Heparan sulfate receptor binding/Transduction (Kern et al., 2003; Opie et al., 2003; Summerford and Samulski, 1998); polyclonal neutralization (Maheshri et al., 2006); C37-B neutralization (Girod et al., 1999; Gurda et al., 2013; Huttner et al., 2003; Wobus et al., 2000); D3 neutralization…”
BackgroundA Highly Emissive Conjugated Polyelectrolyte Vector for Gene Delivery and Transfection
Feng, X., Lv, F., Liu, L., Yang, Q., Wang, S., & Bazan, G. C. (2012) · Advanced Materials · doi:10.1002/adma.201202145 · Cited by 68
Koerber, J. T., Jang, J.-H., Yu, J. H., Kane, R. S., & Schaffer, D. V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.139 · Cited by 64
Self-citationLorain, S., Gross, D.-A., Goyenvalle, A., Danos, O., Davoust, J., & Garcia, L. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300377 · Cited by 62
Murphy, S. L., Li, H., Zhou, S., Schlachterman, A., & High, K. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300334 · Cited by 62
Brown, D., Altermatt, M., Dobreva, T., Chen, S., Wang, A., Thomson, M., & Gradinaru, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730825 · Cited by 60
Barua, S., & Rege, K. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.007 · Cited by 72
AAV Engineering for Improving Tropism to the Central Nervous System
Ghauri, M. S., & Ou, L. (2023) · Biology · doi:10.3390/biology12020186 · Cited by 73
“applied this technique, combined with error-prone PCR, to the AAV2 capsid gene to improve the functional escape of neutralizing antibodies [49].”
MethodNext Step in Gene Delivery: Modern Approaches and Further Perspectives of AAV Tropism Modification
Korneyenkov, M. A., & Zamyatnin, A. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050750 · Cited by 68
“The transduction properties of the novel capsids were also analyzed with cell cultures HEK293 and Chinese hamster ovary (CHO) in the presence of a soluble heparin and two cell cultures with a reduced expression of heparan sulfate, where the same results were obtained [87,89].”
MethodResultGene therapy and neurodevelopmental disorders
Gray, S. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.024 · Cited by 64
Crossing the blood–brain-barrier with viral vectors
Fu, H., & McCarty, D. M. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.006 · Cited by 62
Advancements in the design and scalable production of viral gene transfer vectors
Sharon, D., & Kamen, A. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26461 · Cited by 59
Innate Immune Response to Viral Vectors in Gene Therapy
Wang, Y., & Shao, W.-W. (2023) · Viruses · doi:10.3390/v15091801 · Cited by 52
Parallel Synthesis and Screening of Polymers for Nonviral Gene Delivery
Barua, S., Joshi, A., Banerjee, A., Matthews, D., Sharfstein, S. T., Cramer, S. M., Kane, R. S., & Rege, K. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800151j · Cited by 69
Electrospun nanofibrous scaffolds for controlled release of adeno-associated viral vectors
Lee, S., Kim, J., Chu, H. S., Kim, G.-W., Won, J., & Jang, J. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2011.06.035 · Cited by 62
Oligonucleotide conjugated multi-functional adeno-associated viruses
Katrekar, D., Moreno, A. M., Chen, G., Worlikar, A., & Mali, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-21742-x · Cited by 57
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
A comprehensive atlas of AAV tropism in the mouse
Walkey, C. J., Snow, K. J., Bulcha, J., Cox, A. R., Martinez, A. E., Ljungberg, M. C., Lanza, D. G., Giorgi, M. D., Chuecos, M. A., Alves‐Bezerra, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.041 · Cited by 68
Holehonnur, R., Luong, J. A., Chaturvedi, D., Ho, A., Lella, S. K., Hosek, M. P., & Ploski, J. E. (2014) · BMC Neuroscience · doi:10.1186/1471-2202-15-28 · Cited by 56
“Numerous AAV serotypes have been isolated from adenoviral stocks [22,23], from humans [24-26] and from primate tissues [24-26]; some AAV serotypes have also been engineered by directed evolution [27-29].”
BackgroundRecessive GM3 synthase deficiency: Natural history, biochemistry, and therapeutic frontier
Bowser, L. E., Young, M., Wenger, O. K., Ammous, Z., Brigatti, K. W., Carson, V. J., Moser, T., Deline, J., Aoki, K., Morlet, T. G., et al. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.01.013 · Cited by 59
Adeno-Associated Virus Vector for Central Nervous System Gene Therapy
Zhu, D., Schieferecke, A. J., Lopez, P. A., & Schaffer, D. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.03.010 · Cited by 56
Self-citationApplying machine learning to predict viral assembly for adeno-associated virus capsid libraries
Marques, A. D., Kummer, M., Kondratov, O., Banerjee, A., Moskalenko, O., & Zolotukhin, S. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.017 · Cited by 55
“20 March This is an open access article under the CC BY-NC-ND license (http can contain hundreds of millions of unique variants that then may be subjected to selective pressures in a method known as directed evolution, whereupon multiple rounds of selection are used to single out the “fittest” sequence or sequences fo…”
Boucas, J., Lux, K., Huber, A., Schievenbusch, S., von Freyend, M. J., Perabo, L., Quadt‐Humme, S., Odenthal, M., Hallek, M., & Büning, H. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1392 · Cited by 55
“AAV libraries [6,8,38,39] and high-throughput selection protocols, tools are available to take this into account”
MethodHarnessing mutagenic homologous recombination for targeted mutagenesis in vivo by TaGTEAM
Finney-Manchester, S. P., & Maheshri, N. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt150 · Cited by 63
“Directed evolution of proteins using in vitro-targeted mutagenesis of single genes has been an effective strategy for increasing enzyme stability, specificity and catalysis (1), enhancing viral vectors for gene therapy (2) and creating microbes that tolerate and/or overproduce desirable metabolites (3).”
Self-citationSite‐Specific Modification of Adeno‐Associated Viruses via a Genetically Engineered Aldehyde Tag
Liu, Y., Fang, Y. H., Zhou, Y., Zandi, E., Lee, C.-L., Joo, K., & Wang, P. (2012) · Small · doi:10.1002/smll.201201661 · Cited by 61
Adeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry
Large, E. E., Silveria, M., Zane, G. M., Weerakoon, O., & Chapman, M. S. (2021) · Viruses · doi:10.3390/v13071336 · Cited by 59
Synthetic virology: engineering viruses for gene delivery
Guenther, C. M., Kuypers, B. E., Lam, M. T., Robinson, T. M., Zhao, J. X., & Suh, J. (2014) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1287 · Cited by 59
Hwang, B.-Y., & Schaffer, D. V. (2013) · Gene Therapy · doi:10.1038/gt.2013.1 · Cited by 59
Self-citationNext-generation AAV vectors for clinical use: an ever-accelerating race
Weinmann, J., & Grimm, D. (2017) · Virus Genes · doi:10.1007/s11262-017-1502-7 · Cited by 55
Zhu, D., Brookes, D. H., Busia, A., Carneiro, A., Fannjiang, C., Popova, G., Shin, D., Donohue, K. C., Lin, L. F., Miller, Z. M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj3786 · Cited by 63
“To minimize cross-packaging, we diluted the plasmid library according to previously determined concentration that minimizes the event of multiple members of the capsid plasmid library entering into the same cell ( 1 , 54 ).”
BackgroundMethodInfluentialSelf-citationRen, D., Fisson, S., Dalkara, D., & Ail, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091973 · Cited by 52
“The best-performing variants selected from this screen were reported to evade antibodies and enhance the gene expression [88].”
BackgroundOptimization of AAV vectors to target persistent viral reservoirs
Colón-Thillet, R., Jerome, K. R., & Stone, D. (2021) · Virology Journal · doi:10.1186/s12985-021-01555-7 · Cited by 50
“The second main approach used to generate AAV capsid libraries utilizes error-prone PCR of the AAV2 cap gene to create functional mutants and has been used to identify capsids with altered receptor binding affinity and the ability to evade neutralizing antibodies [63, 64].”
MethodNance, M. E., & Duan, D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.107 · Cited by 51
“155 This strategy led to the isolation of AAV-r2.”
Judd, J., Wei, F., Nguyen, P. Q., Tartaglia, L. J., Agbandje-McKenna, M., Silberg, J. J., & Suh, J. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.46 · Cited by 51
Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia
Ajufo, E., & Cuchel, M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0579-0 · Cited by 51
Metadata
- Authors
- Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V.
- Affiliations
- University of California, Berkeley (US)
- Abigail Wexner Research Institute (US)
- Corresponding author
- Schaffer, David V
- Venue
- Nature Biotechnology
- Published
- 2006-01-22
- Volume
- 24
- Issue
- 2
- Pages
- 198-204
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2102111681
- Cited by
- 538
- References
- 53
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 29 · 2023: 31 · 2022: 31 · 2021: 25 · 2020: 31 · 2019: 33 · 2018: 19 · 2017: 26 · 2016: 23 · 2015: 33 · 2014: 32 · 2013: 31 · 2012: 23
- FWCI
- 15.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- ALS Association
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus, AAV2, directed evolution, viral capsid, gene delivery vectors, heparin binding, antibody neutralization, high-throughput selection
- MeSH terms
- Adenoviridae, Genetic Vectors, Transfection, Genetic Therapy, Drug Delivery Systems, Gene Targeting, Directed Molecular Evolution, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.